Calendar

««Mar 2010»»
SMTWTFS
  123456
78910111213
14151617181920
21222324252627
28293031
  More

Search Box

 

cbt and mindfulness

Mailing List

RSS Feeds








Add to Jamespot
Widgetize!

Translate

Disclaimer

All content within Anxiety Insights is provided for general information only, and should not be treated as a substitute for the medical advice of your doctor or other health care professional.

Anxiety Insights is not responsible or liable for any diagnosis made by a reader based on the content of this website.

Anxiety Insights is not liable for the contents of any external internet sites listed, nor does it endorse any commercial product or service mentioned or advised on any of the sites.

Always consult your doctor if you are in any way concerned about your health.

Recommended links

Depression is Real's Down & Up Show
Weekly audio-casts from the Depression Is Real Coalition

Teen Drug Abuse Intervention
Help fight teen drug abuse, we provide information to help fight teen drug abuse by prevention and intervention.
www.teendrugabuse.us


we support

Kiva.org - micro loans that change lives

Moving a Nation to Care : Post Traumatic Stress Disorder and America's Returning Troops, by Ilona Meagher

No Longer Lonely.com

"just don't smoke"


"Don't smoke, whatever you do, just don't smoke."
                        Yul Brynner

Hit Counter

Total: 3,602,686
since: 14 May 2006

Abstract+: Issues in the pharmacological treatment of Obsessive-Compulsive Disorder

posted Thursday, 26 July 2007

Int J Clin Pract. 2007;61(7):1170-1180.

Issues In The Pharmacological Treatment of Obsessive-Compulsive Disorder

Math SB, Janardhan Reddy YC.

Aims: Obsessive-compulsive disorder (OCD) preferentially responds to a class of antidepressants called serotonin reuptake inhibitors.[SRI] This review discusses certain issues unique to pharmacological treatment of OCD: choice of SRI, dose and duration of treatment, options after first failed SRI trial and treatment of SRI non-responders.

Methods: We performed a MEDLINE search for pharmacotherapy studies published until December 2006. In addition, the reference sections of major articles, and reviews were also screened. We also considered clinical guidelines and narrative reviews in writing this review.

Results: The SRIs are equally effective in treating OCD. Meta-analyses suggest that clomipramine may be superior to other SRIs. OCD tends to respond to higher doses of SRIs than that used to treat depression. Response to treatment is usually delayed and may take up to 8-12 weeks. Atypical antipsychotics are the only proven augmenting agents in SRI non-responders. Cognitive behaviour therapy (CBT) is an effective treatment strategy in treating OCD and possibly has a role in treating SRI non-responders.

Discussion: Side effect profile and drug-drug interactions largely determine the choice of SRI. Those who fail to respond to one SRI trial may well respond to another SRI trial. Clomipramine is recommended if 2-3 trials of SRIs fail to produce response. Atypical antipsychotics are the first-line augmenting agents in SRI non-responders. CBT should be considered in all patients with OCD and is a potential option in SRI non-responders.

Conclusion: OCD is a chronic and debilitating disorder. In responders, SRIs have to be continued in the same doses (if possible) for a minimum of 1-2 years and may be lifelong in those with persistent symptoms and in those with multiple relapses. CBT has to be offered in combination with SRIs wherever facilities for CBT exist.

(Text has been reformatted for clarity; ed.)

Source + Full article text...   (Medscape - Free registration required)

tags:      

links: digg this    del.icio.us    technorati    reddit